439085-51-5Relevant academic research and scientific papers
An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus
Feil, Susanne C.,Hamilton, Stephanie,Krippner, Guy Y.,Lin, Bo,Luttick, Angela,McConnell, Darryl B.,Nearn, Roland,Parker, Michael W.,Ryan, Jane,Stanislawski, Pauline C.,Tucker, Simon P.,Watson, Keith G.,Morton, Craig J.
, p. 303 - 307 (2012)
Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds
Antiviral agents
-
Page/Page column 24, (2016/05/02)
This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as nove
ANHYDROUS CRYSTALLINE FREE BASE FORM OF-{2-[1-(6-METHYL-3-PYRIDAZINYL)-4-PIPERIDINYL]ETHOXY}-3-ETHOXY-1,2-BENZISOXAZOLE
-
Page/Page column 38; 40; 41, (2016/07/11)
A crystalline form of 6-{2-[l-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}- 3-ethoxy-l,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form i
Antiviral agents
-
, (2008/06/13)
This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel
